Zobrazeno 1 - 10
of 20 878
pro vyhledávání: '"BISPHOSPHONATES"'
Publikováno v:
Discover Nano, Vol 19, Iss 1, Pp 1-27 (2024)
Abstract Breast cancer (BC) bone metastasis poses a significant clinical challenge due to its impact on patient prognosis and quality of life. Curcumin (CUR), a natural polyphenol compound found in turmeric, has shown potential in cancer therapy due
Externí odkaz:
https://doaj.org/article/1ceb8884b6c14223a6865df4b2e98b06
Publikováno v:
Clinical Pediatric Hematology-Oncology, Vol 31, Iss 2, Pp 36-40 (2024)
Pediatric acute leukemia presenting with osteolytic lesions and hypercalcemia is an unusual and rare occurrence. We are reporting two such cases with atypical presentations. The first case involved a 10-year-old boy who complained of progressively wo
Externí odkaz:
https://doaj.org/article/cd959227109f420494c0c87e3cde79d0
Publikováno v:
Научно-практическая ревматология, Vol 62, Iss 4, Pp 369-376 (2024)
Osteoporosis (OP) is a disease characterized by a decrease in bone strength, leading to an increased risk of fractures. Bone fragility in children may be due to genetic disorders, chronic underlying conditions or taking medications that negatively af
Externí odkaz:
https://doaj.org/article/26bac7f82ef44a638a2fac5af3e3c59c
Publikováno v:
AACE Clinical Case Reports, Vol 10, Iss 5, Pp 170-173 (2024)
Background/Objective: Atypical femur fractures (AFFs) caused by long-term bisphosphonate use are associated with high rates of delayed healing and nonunion. Case Report: A 64-year-old woman with osteopenia on alendronate for 15 years sustained a disp
Externí odkaz:
https://doaj.org/article/bc60e5e1a390404f91c7147bb8199222
Publikováno v:
World Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 10, Iss 3, Pp 237-240 (2024)
Abstract Introduction Medication‐related osteonecrosis of the temporal bone is rare and has been reported to be associated with the use of anti‐resorptive and biologic agents. Here, we present the first case of tyrosine‐kinase inhibitor‐relat
Externí odkaz:
https://doaj.org/article/77d8712cf8e94871913d0ba9f855cdd2
Autor:
Bruna Cristina de Cristo, Hassan Yousef Saleh, Suyany Weiss, Aline Sebastiani, Mohammed Elsalanty, Rafaela Scariot, Tatiana Miranda Deliberador
Publikováno v:
Saudi Dental Journal, Vol 36, Iss 11, Pp 1456-1458 (2024)
Purpose: The aim of this work was to evaluate the effectiveness of a gel with active oxygen in the prevention of MRONJ. Methods: Using split-mouth study design, twelve Wistar rats were used, females (n = 6) and males (n = 6). All rats received a week
Externí odkaz:
https://doaj.org/article/c273bde2e8a443bba896cca8c57c79f3
Autor:
Lu Tao, Ying Gao, Yushen Li, Liuqing Yang, Jingjing Yao, Handan Huang, Jinling Yu, Bing Han, Bowei Wang, Zhihui Liu
Publikováno v:
BMC Oral Health, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Medication-related osteonecrosis of the Jaw (MRONJ) is a rare but severe side effect in patients treated with medications such as Bisphosphonates (BPs). Its pathophysiological mechanism needs to be more precise. Establishing preve
Externí odkaz:
https://doaj.org/article/171a52b091ed467390cc132a05f42084
Publikováno v:
eJHaem, Vol 5, Iss 4, Pp 669-676 (2024)
Abstract Novel treatments in multiple myeloma (MM) could influence the incidence of skeletal‐related events (SREs). We aimed to examine the incidence of SRE and the preventive use of osteoclast inhibitors (OIs) in a cohort of MM patients in the era
Externí odkaz:
https://doaj.org/article/48e1d7a9cd82446eb0adca2c26e4c96f
Publikováno v:
BMC Oral Health, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Osteogenesis imperfecta (OI) is an inherited disorder characterized by bone fragility and skeletal alterations. The administration of bisphosphonates (BPs) to patients with OI reduces pain, thereby improving their quality of life.
Externí odkaz:
https://doaj.org/article/94821e6bde524eaaa8917f489c9b61ba
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 2, Pp 190-200 (2024)
INTRODUCTION. Osteoporosis is a leading cause of morbidity, disability, reduced quality of life, and premature mortality in the elderly population. Denosumab is a treatment for osteoporosis; however, denosumab discontinuation may cause a rebound effe
Externí odkaz:
https://doaj.org/article/fdbf7028a4be4045bb00a1d7a5195737